| 1 |
NCT02074943 |
Unknown † |
Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia |
|
|
Interventional |
Not Applicable |
- Vancouver General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The degree of hair regrowth based on the hair regrowth score (RGS) for each side of scalp.
- Changes in hair count and caliber. Changes in hair count and caliber
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02074943 |
H13-03126 |
|
April 2014 |
June 2015 |
December 2015 |
February 28, 2014 |
December 11, 2014 |
|
- The Skin Care Center, Vancouver General Hospital
Vancouver, Canada
|
| 2 |
NCT01227031 |
Unknown † |
Pharmacogenomic Study of Androgenetic Alopecia |
|
|
Observational |
|
- Taipei Medical University WanFang Hospital
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
400 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT01227031 |
98089 |
|
October 2010 |
October 2010 |
July 2011 |
October 22, 2010 |
November 12, 2010 |
|
- Taipei Medical University-Wan Fang Hospital
Taipei, Taiwan
|
| 3 |
NCT01052870 |
Completed |
Association of Polymorphisms in the Androgen Receptor Gene and Finasteride Response in Women With Androgenetic Alopecia |
|
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single
- Primary Purpose: Treatment
|
|
12 |
Female |
Child, Adult, Senior |
NCT01052870 |
HairDx2009 |
|
December 2008 |
December 2009 |
December 2009 |
January 20, 2010 |
January 20, 2010 |
|
|
| 4 |
NCT01701271 |
Completed
Has Results |
Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females |
|
- Other: Hair loss prevention lotion
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change of the Amount of Hair Loss in a Pull Test
- Change of the Density of the Hair on a Polarized Light Video-camera as a Measure of Efficacy.
- Change of Sebum on a Sebum-meter
|
20 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01701271 |
MEXIS-HAIR LOSS-STUDY 1.2012 |
MEXISPATENT |
February 2001 |
June 2001 |
June 2001 |
October 5, 2012 |
February 17, 2016 |
February 17, 2016 |
- George Mexis
Athens, Greece
|
| 5 |
NCT02503137 |
Completed |
A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing |
|
- Drug: Topical SM04554 solution
- Drug: Topical Vehicle solution
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in number of terminal hair follicles
- Change in number of anagen hair follicles
- Change in number of telogen hair follicles
- (and 7 more...)
|
49 |
Male |
18 Years to 65 Years (Adult) |
NCT02503137 |
SM04554-AGA-04 |
|
August 2015 |
April 2016 |
April 2016 |
July 20, 2015 |
July 14, 2016 |
|
- Research Site
Clinton Township, Michigan, United States - Research Site
Cleveland, Ohio, United States - Research Site
College Station, Texas, United States - (and 2 more...)
|
| 6 |
NCT02198261 |
Active, not recruiting |
Minoxidil Response Testing in Males With Androgenetic Alopecia |
|
- Drug: 5% minoxidil topical foam
|
Observational |
|
|
Industry |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the mean change in non-vellus hair count in the target region
- Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the subjects ratings
- Sensitivity and specificity of the minoxidil response in-vitro diagnostic kit to predict at baseline the treatment efficacy evaluated by expert panel review of global photographs assessing hair regrowth
- (and 2 more...)
|
300 |
Male |
18 Years to 49 Years (Adult) |
NCT02198261 |
AB-IVD-MINOXIDIL-003 |
|
July 2014 |
December 2017 |
December 2017 |
July 23, 2014 |
January 24, 2017 |
|
- Physicians Hair Institute
Tucson, Arizona, United States - Tennessee Clinical Research Center
Nashville, Tennessee, United States - Sinclair Dermatology
East Melbourne, Australia - (and 2 more...)
|
| 7 |
NCT01286649 |
Completed |
Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia |
|
- Other: Human autologous hair follicle cells
- Other: Cell medium
|
Interventional |
Phase 1
Phase 2 |
- TrichoScience Innovations, Inc.
- Pharmalog Institut für klinische Forschung GmbH (PHARMALOG Institute for Clinical Research)
- PRA Health Sciences
- (and 4 more...)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Incidence of local adverse events
- Systemic adverse events
- Histopathological analysis
- (and 2 more...)
|
19 |
All |
18 Years to 55 Years (Adult) |
NCT01286649 |
TS001-2009 |
|
December 2010 |
April 2012 |
February 23, 2017 |
January 31, 2011 |
March 8, 2017 |
|
- Scientific Research Institute for Skin and Venereal Diseases, Department of Dermatology
Tbilisi, Georgia
|
| 8 |
NCT03495817 |
Recruiting
New |
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution |
|
|
Interventional |
Phase 2 |
- Aclaris Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in Target Area Hair Count (TAHC)
- Change from baseline in cumulative Target Area Hair Width
- Development of new hair growth using a seven-point rating scale
|
24 |
All |
18 Years to 50 Years (Adult) |
NCT03495817 |
ATI-50002-AGA-201 |
|
March 22, 2018 |
October 30, 2018 |
October 30, 2018 |
April 12, 2018 |
April 17, 2018 |
|
- Aclaris Investigational Site
Denver, Colorado, United States - Aclaris Investigational Site
Portland, Oregon, United States - Aclaris Investigational Site
Austin, Texas, United States
|
| 9 |
NCT03048461 |
Not yet recruiting |
The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia |
|
- Device: Platelet Rich Plasma Prep System
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Clinical change of androgenetic alopecia, as determined by scoring photographs
|
30 |
All |
18 Years to 55 Years (Adult) |
NCT03048461 |
MA04222016 |
|
May 2018 |
August 2018 |
February 2019 |
February 9, 2017 |
February 21, 2018 |
|
- Northwestern University Department of Dermatology
Chicago, Illinois, United States
|
| 10 |
NCT02848300 |
Completed |
Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia |
|
- Drug: Bimatoprost 1% Formulation A
- Drug: Bimatoprost 1% Formulation B
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Drug Concentration in Skin Biopsy Samples
- Percentage of Participants with at Least 1 Treatment Emergent Adverse Event
|
11 |
Male |
18 Years to 49 Years (Adult) |
NCT02848300 |
1666-101-012 |
|
July 2016 |
October 2016 |
October 2016 |
July 28, 2016 |
October 26, 2016 |
|
- DermResearch, LLC
Austin, Texas, United States
|
| 11 |
NCT02528552 |
Active, not recruiting |
Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO |
|
- Device: LH80 PRO
- Device: Sham Device
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hair growth
- Quantitative Hair Growth
- Subject Self Assessment
|
80 |
Male |
18 Years to 50 Years (Adult) |
NCT02528552 |
CR-PRC-001 |
|
August 2015 |
October 2016 |
December 2016 |
August 19, 2015 |
December 2, 2016 |
|
- Axis Clinical Tirals
Los Angeles, California, United States - MedaPhase, Inc.
Newnan, Georgia, United States - NW Dermatology & Research Center, LLC
Portland, Oregon, United States - Tennessee Clinical Research Center
Nashville, Tennessee, United States
|
| 12 |
NCT01501617 |
Unknown † |
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia |
|
- Biological: Hair Stimulating Complex (HSC)
- Device: Dulbecco's Modified Eagle Medium, DMEM
|
Interventional |
Phase 1
Phase 2 |
- Histogen
- Gleneagles CRC Pte Ltd.
|
Industry / Other |
- Allocation: Randomized
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Systemic safety measures will be assessed by measuring vital signs, adverse experiences, laboratory tests (hematology, clinical chemistry and urinalysis)and immunological response (anti-drug antibodies)
- Non-vellus hair counts
- Hair Thickness Density
- Local safety measures will be assessed by clinical exam of treatment areas and monitoring adverse events
|
56 |
Male |
21 Years to 65 Years (Adult) |
NCT01501617 |
11-HIS006-PH |
HSC Phase I/II |
December 2011 |
June 2012 |
December 2012 |
December 29, 2011 |
January 18, 2012 |
|
- The Medical City
Pasig City, Manila, Philippines
|
| 13 |
NCT02154503 |
Unknown † |
Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia |
|
- Device: topical 5% Minoxidil (Microneedling)
|
Interventional |
Phase 1 |
- Vancouver General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hair caliber diameter and hair counts will be measured on both the treated and untreated sides.
- Adverse effects of the procedure will be recorded.
|
20 |
Male |
18 Years to 65 Years (Adult) |
NCT02154503 |
H13-03501 |
|
April 2014 |
March 2017 |
March 2017 |
June 3, 2014 |
June 3, 2014 |
|
- The Skin Care Centre
Vancouver, British Columbia, Canada
|
| 14 |
NCT02591355 |
Recruiting |
Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment |
|
- Device: Autologous Platelet Rich Plasma
- Device: Saline solution injection
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Evaluate the changes in hair density of androgenetic alopecia
- Evaluate the changes of hair diameter and hair shedding in androgenetic alopecia
|
50 |
All |
18 Years to 60 Years (Adult) |
NCT02591355 |
RL 03 |
|
September 6, 2017 |
March 2018 |
March 2018 |
October 29, 2015 |
October 25, 2017 |
|
- NYU Dermatologic Associates
New York, New York, United States
|
| 15 |
NCT01967277 |
Completed
Has Results |
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy |
|
- Device: Handi-Dome Laser
- Device: Incandescent red light source.
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects.
- Absolute Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects.
|
44 |
Female |
18 Years to 60 Years (Adult) |
NCT01967277 |
USC650 |
|
March 2014 |
August 2014 |
September 2014 |
October 22, 2013 |
May 6, 2015 |
May 6, 2015 |
- Bodian Dermatology
Great Neck, New York, United States - Center for Aesthetic Dermatology
Woodbury, New York, United States
|
| 16 |
NCT02275351 |
Completed |
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) |
|
- Drug: SM04554
- Drug: Vehicle
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in non-vellus hair count
- Change in subject assessment of hair growth and quality
- Change in hair growth as assessed by the investigator
- (and 2 more...)
|
310 |
Male |
18 Years to 55 Years (Adult) |
NCT02275351 |
SM04554-AGA-02 |
|
November 2014 |
November 2015 |
November 2015 |
October 27, 2014 |
November 26, 2015 |
|
- Encinitas, California, United States
- San Diego, California, United States
- New Haven, Connecticut, United States
- (and 21 more...)
|
| 17 |
NCT02067260 |
Completed |
A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males |
|
- Device: X5 HairLaser
- Device: X5 Hair Laser Sham Device
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- Difference in terminal hair count in the target region
- Subject's static self global assessment of hair regrowth
|
|
Male |
20 Years to 60 Years (Adult) |
NCT02067260 |
08-02-31-161 |
|
|
April 2010 |
|
February 20, 2014 |
February 20, 2014 |
|
- Burke Pharmaceutical Research
Hot Springs, Arkansas, United States - Hilltop Research
St. Petersburg, Florida, United States - NYU School of Medicine
New York, New York, United States
|
| 18 |
NCT02279823 |
Completed |
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia |
|
- Drug: CB-03-01 solution
- Drug: Minoxidil Solution 5%
- Drug: Placebo solution
|
Interventional |
Phase 2 |
- Intrepid Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change in Target Area Hair Count (TAHC)
- Subject Self Assessment (Hair Growth Assessment [HGA])
- Change in Target Area Hair Width (TAHW)
- (and 3 more...)
|
95 |
Male |
18 Years to 50 Years (Adult) |
NCT02279823 |
171-7152-201 |
|
October 2014 |
December 2015 |
May 2016 |
October 31, 2014 |
March 13, 2017 |
|
- Therapeutics Clinical Research
San Diego, California, United States - Minnesota Clinical Study Center
Fridley, Minnesota, United States - DermResearch, Inc.
Austin, Texas, United States
|
| 19 |
NCT01885676 |
Unknown † |
Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia |
|
- Device: PRGF-Endoret
- Other: Saline Solution
|
Interventional |
Not Applicable |
- Biotechnology Institute IMASD
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in Hair density at three months (number of hairs per cm2)
- Hair Width (micrometers)
- Anagen/telogen ratio
- (and 2 more...)
|
24 |
All |
18 Years to 65 Years (Adult) |
NCT01885676 |
BTI-01D-EC/12/ALO |
|
|
February 2014 |
|
June 25, 2013 |
June 25, 2013 |
|
- Clínica Eduardo Anitua.
Vitoria, Alava, Spain - Centro dermatológico estético
Alicante, Spain
|
| 20 |
NCT01643629 |
Unknown † |
A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia |
|
- Biological: Autologous Human Platelet Lysate (HPL)
- Other: 2 % Minoxidil and /or Finasteride
|
Interventional |
Phase 1
Phase 2 |
- Kasiak Research Pvt. Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Calibre & Density of Hair as assessed by Folliscope
- Photographic Assessment
|
20 |
Male |
18 Years to 50 Years (Adult) |
NCT01643629 |
KRPL/HPL-AGA/11-12/001A |
|
January 2012 |
October 2012 |
November 2012 |
July 18, 2012 |
July 25, 2012 |
|
- Kasiak Research Pvt Ltd
Thane, Maharashtra, India
|
| 21 |
NCT01644422 |
Unknown † |
Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant |
|
- Biological: Autologous Human Platelet Lysate
- Other: Standard hair follicle transplant
|
Interventional |
Phase 1
Phase 2 |
- Kasiak Research Pvt. Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Improvement in Calibre & Density of Hair as assessed by Folliscope
- Photographic assessment
|
30 |
Male |
18 Years to 50 Years (Adult) |
NCT01644422 |
KRPL/HPL-AGA/11-12/001B |
|
January 2012 |
October 2012 |
November 2012 |
July 19, 2012 |
July 25, 2012 |
|
- Kasiak Research Pvt Ltd
Thane, Maharashtra, India
|
| 22 |
NCT01231607 |
Completed
Has Results |
Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia |
|
- Drug: 1mg Finasteride active
- Drug: 0.02mg dutasteride
- Drug: 0.1mg dutasteride
- (and 3 more...)
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline (BL) in Target Area Hair Count (HC) Within a 2.54 Centimeter (cm) (1 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by Macrophotographic Technique (MT)
- Change From Baseline in Target Area Hair Count Within a 1.13 cm (0.44 Inch) Diameter Circle at the Vertex at Week 24, as Assessed by MT
- Change From Baseline in Target Area Hair Count Within a 2.54 cm (1 Inch) Diameter Circle at the Vertex at Week 12 as Assessed by MT
- (and 14 more...)
|
917 |
Male |
20 Years to 50 Years (Adult) |
NCT01231607 |
114263 |
|
October 2010 |
February 2012 |
February 2012 |
November 1, 2010 |
January 11, 2017 |
October 4, 2012 |
- GSK Investigational Site
Caba, Buenos Aires, Argentina - GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina - GSK Investigational Site
La Boca, Buenos Aires, Argentina - (and 36 more...)
|
| 23 |
NCT01319370 |
Completed |
Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia |
|
- Drug: Minoxidil
- Drug: vehicle of 5% Minoxidil topical foam
|
Interventional |
Phase 2 |
- Natalie GARCIA BARTELS
- Johnson & Johnson
- Charite University, Berlin, Germany
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change of target area non-vellus hair count in the temple region (t-TAHC) [n/cm²] compared to baseline after 24 weeks
- Assessing the investigational products safety by means of clinical examination (local intolerance, AE, SAE)
- Change of cumulative hair width in non-vellus hair in temple and vertex region (t-TAHW; v-TAHW) [mm/cm²] compared to baseline after 24, 52, 76 and 104 weeks
- (and 2 more...)
|
70 |
Male |
18 Years to 70 Years (Adult, Senior) |
NCT01319370 |
CRC-AGA02
2010-018291-25 |
|
November 2010 |
March 2013 |
March 2013 |
March 21, 2011 |
November 7, 2013 |
|
- Charité-Universitätsmedizin Berlin, Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergy
Berlin, Germany
|
| 24 |
NCT02483195 |
Withdrawn |
The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia |
- Female Androgenetic Alopecia
|
- Drug: 5% Minoxidil
- Drug: 200mg Spironolactone
- Drug: 5mg Finasteride
- Other: Placebo
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The Savin Scale will be used to determine hair growth and/or hair loss between the groups.
- The Ludwig Scale will be used to determine hair growth and/or hair loss between the groups.
- Alopecia improvement assessment will be used to determine hair growth and/or hair loss between the groups.
|
0 |
Female |
60 Years and older (Adult, Senior) |
NCT02483195 |
IRB201500433 |
|
August 2016 |
August 2018 |
August 2018 |
June 26, 2015 |
September 2, 2016 |
|
- UF Health
Gainesville, Florida, United States
|
| 25 |
NCT02999737 |
Active, not recruiting |
Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia |
|
- Biological: Platelet Rich Plasma for 4 sessions
- Biological: Platelet rich plasma for 2 sessions
|
Interventional |
Phase 4 |
- Skin Care and Laser Physicians of Beverly Hills
- Eclipse Aesthetics, LLC
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent change in terminal hair counts
- Percent change in terminal hair shaft caliber
- Degree of hair shedding
- (and 3 more...)
|
40 |
All |
18 Years to 65 Years (Adult) |
NCT02999737 |
AGA-2016 |
|
November 2016 |
August 2017 |
August 2017 |
December 21, 2016 |
January 12, 2017 |
|
- Skincare and Laser Physicians of Beverly Hills
Los Angeles, California, United States
|
| 26 |
NCT00958750 |
Completed |
Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia |
- Androgenetic Alopecia
- Female Pattern Hair Loss
|
|
Interventional |
Phase 3 |
- Charite University, Berlin, Germany
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Change of target area non-vellus hair count (TAHC) [n/cm²] after 24 weeks
- Assessing the investigational products safety by means of clinical examination (local intolerance, facial hypertrichosis, AE, SAE) and blood Minoxidil level (baseline + week 24)
- Change of cumulative hair width in non-vellus hair (TAHW) after 24 weeks
- (and 2 more...)
|
113 |
Female |
18 Years and older (Adult, Senior) |
NCT00958750 |
CRC-AGA01
EudraCT: 2008-001770-33 |
|
June 2008 |
February 2009 |
June 2009 |
August 13, 2009 |
November 18, 2011 |
|
- Charité-Universitaetsmedizin; Clinical Research Center for Hair and Skin Science
Berlin, Germany
|
| 27 |
NCT02865421 |
Completed |
Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia |
- Combination of SVF and PRP for Androgenetic Alopecia
|
- Drug: stem cells
- Drug: platelet rich plasma
|
Interventional |
Phase 2 |
- King Edward Medical University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
22 |
All |
15 Years to 70 Years (Child, Adult, Senior) |
NCT02865421 |
King Edward Medical University |
AGA |
June 10, 2017 |
August 12, 2017 |
December 31, 2017 |
August 12, 2016 |
January 11, 2018 |
|
- King Edward Medical University
Lahore, Punjab, Pakistan
|
| 28 |
NCT00947505 |
Completed
Has Results |
Treatment of Androgenetic Alopecia in Males |
- Androgenetic Alopecia
- Hair Loss
- Male Pattern Baldness
|
- Device: HairMax LaserComb 2009, 7 Beam
- Device: HairMax LaserComb
|
Interventional |
Not Applicable |
- Lexington International, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Terminal Hair Count at 16 and 26 Weeks Over Baseline
|
49 |
Male |
25 Years to 60 Years (Adult) |
NCT00947505 |
7 2009-M-01 |
|
August 2009 |
August 2010 |
August 2010 |
July 28, 2009 |
July 30, 2012 |
July 30, 2012 |
- Abe Marcadis, M.D.
Palm Beach, Florida, United States - Michael Jarratt, MD
Austin, Texas, United States
|
| 29 |
NCT01016964 |
Completed
Has Results |
Treatment of Androgenetic Alopecia in Females, 12 Beam |
- Androgenetic Alopecia
- Hair Loss
- Female Pattern Baldness
|
- Device: HairMax LaserComb 2009 model 12 beam
- Device: Sham Device
|
Interventional |
Not Applicable |
- Lexington International, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Hair Count at 16 and 26 Weeks Over Baseline
|
63 |
Female |
25 Years to 60 Years (Adult) |
NCT01016964 |
12 2009-F-02 |
|
January 2010 |
March 2011 |
March 2011 |
November 20, 2009 |
September 7, 2012 |
September 7, 2012 |
- University of Miami Miller School of Medicine - Dermatology
Miami, Florida, United States - University of Minnesota, Department of Dermatology
Minneapolis, Minnesota, United States - Cleveland Clinic Foundation - Department of Dermatology
Cleveland, Ohio, United States
|
| 30 |
NCT01226459 |
Completed
Has Results |
Clinical Trial in Females for Female Pattern Hair Loss |
|
- Drug: 5% Minoxidil Topical Foam
- Drug: Vehicle Topical Foam
|
Interventional |
Phase 3 |
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
- Johnson & Johnson Consumer and Personal Products Worldwide
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Target Area Hair Count
- Subject Assessment of Scalp Coverage
|
404 |
Female |
18 Years and older (Adult, Senior) |
NCT01226459 |
MINALO3005
2010-019881-96 |
|
September 2010 |
August 2011 |
August 2011 |
October 22, 2010 |
June 10, 2014 |
June 3, 2014 |
- Axis Clinical Trials
Los Angeles, California, United States - Axis Clinical Trials
Los Angeles, California, United States - Therapeutics Clinical Research
San Diego, California, United States - (and 14 more...)
|
| 31 |
NCT01309191 |
Completed |
Microarray Analysis of Scalp Biopsies After Minoxidil Treatment |
|
- Drug: Minoxidil
- Other: Placebo
|
Interventional |
Not Applicable |
- University Hospitals Cleveland Medical Center
- University of California, San Francisco
- Kaiser Permanente
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Analysis of change in gene expression before and after topical minoxidil application
- Differences ing ene expression in two different regions of the scalp, frontal and vertex.
|
14 |
Male |
18 Years to 49 Years (Adult) |
NCT01309191 |
12-10-24
338259 |
|
April 2011 |
April 2012 |
April 2012 |
March 7, 2011 |
February 27, 2014 |
|
- Skin Study Center, UH Case Medical Center
Cleveland, Ohio, United States
|
| 32 |
NCT02791243 |
Completed |
Photosensitization Study in Androgenetic Alopecia |
|
- Drug: Finasteride 0.25%
- Drug: Placebo for Finasteride 0.25%
- Drug: Negative Control
|
Interventional |
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Potential for induction of photosensitization
|
58 |
Male |
18 Years to 65 Years (Adult) |
NCT02791243 |
PM1542 |
|
May 9, 2016 |
June 2016 |
June 27, 2016 |
June 6, 2016 |
May 18, 2017 |
|
- Princeton Consumer Research Inc.
Chelmsford,, Essex, United Kingdom
|
| 33 |
NCT00981461 |
Completed
Has Results |
Treatment of Androgenetic Alopecia in Females, 9 Beam |
- Androgenetic Alopecia
- Hair Loss
- Female Pattern Baldness
|
- Device: HairMax LaserComb
- Device: Control Device
|
Interventional |
Not Applicable |
- Lexington International, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Terminal Hair Count Week 16 and 26 Weeks Over Baseline
|
72 |
Female |
25 Years to 60 Years (Adult) |
NCT00981461 |
151.0805 |
|
October 2009 |
October 2010 |
October 2010 |
September 22, 2009 |
August 10, 2012 |
July 30, 2012 |
- Jose Mendez, DO
Miami, Florida, United States - Abe Marcadis, MD
Palm Beach, Florida, United States - David Goldberg, MD
Hackensack, New Jersey, United States - (and 2 more...)
|
| 34 |
NCT00471510 |
Unknown † |
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss |
|
- Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hair density, hair growth rate, hair diameter as measured using the Trichoscan method
- Assessment score of dermal tolerability
- Physician's global assessment score
|
140 |
Male |
18 Years to 49 Years (Adult) |
NCT00471510 |
NEOSH101-CLIN-AGA004 |
|
May 2007 |
February 2008 |
|
May 10, 2007 |
May 20, 2008 |
|
- bioskin Institute for Dermatological Research and Development GmbH
Hamburg, Germany
|
| 35 |
NCT00418730 |
Completed |
Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss |
|
- Drug: tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Hair density, hair growth rate, hair diameter as measured using the TrichoScan method
- Assessment score of dermal tolerability
- Physician's global assessment score
|
180 |
Male |
18 Years to 49 Years (Adult) |
NCT00418730 |
NEOSH101-CLIN-AGA003 |
|
January 2007 |
October 2007 |
April 2008 |
January 5, 2007 |
May 20, 2008 |
|
- bioskin Institute for Dermatological Research and Development GmbH
Hamburg, Germany
|
| 36 |
NCT01437163 |
Completed |
Treatment of Androgenetic Alopecia in Males and Females |
|
- Device: TopHat 655 rejuvenation system
- Device: Laser and/or Light Hair Rejuvenation System
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percentage Increase of Terminal Hairs from Pre-treatment, Baseline Count
|
88 |
All |
18 Years to 60 Years (Adult) |
NCT01437163 |
ApiraTH655 |
LLLT |
September 2011 |
August 2013 |
August 2013 |
September 20, 2011 |
July 12, 2016 |
|
- Adolfo Fernandez-Obregon, MD
Hoboken, New Jersey, United States - Peter S. Halperin, MD
New York, New York, United States - Raymond J. Lanzafame, MD
Rochester, New York, United States - Jeffrey A. Sklar, MD
Woodbury, New York, United States
|
| 37 |
NCT00965640 |
Completed |
Treatment of Male Pattern Baldness With Botulinum Toxin |
|
- Drug: Botulinum Toxin - A injections
|
Interventional |
Phase 2 |
|
Other |
- Primary Purpose: Screening
|
|
|
Male |
18 Years to 65 Years (Adult) |
NCT00965640 |
MPB-2002-01
HPB 081023 |
|
December 2002 |
June 2004 |
June 2004 |
August 25, 2009 |
August 25, 2009 |
|
- Crown Institute
Pickering, Ontario, Canada
|
| 38 |
NCT00947219 |
Completed
Has Results |
Treatment of Androgenic Alopecia in Males |
- Androgenetic Alopecia
- Hair Loss
- Male Pattern Baldness
|
- Device: HairMax LaserComb
- Device: Control device
|
Interventional |
Not Applicable |
- Lexington International, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Terminal Hair Count at 16 and 26 Weeks Compared to Baseline in Men Diagnosed With Androgenetic Alopecia
|
79 |
Male |
25 Years to 60 Years (Adult) |
NCT00947219 |
9.12 2009-M-02 |
|
July 2009 |
August 2010 |
August 2010 |
July 28, 2009 |
January 31, 2013 |
January 31, 2013 |
- Abe Marcadis, M.D.
West Palm Beach, Florida, United States - David Goldberg, M.D.
Hackensack, New Jersey, United States - Zoe Draelos, M.D.
High Point, North Carolina, United States
|
| 39 |
NCT02626780 |
Completed |
Adipose-derived SVF for Treatment of Alopecia |
|
|
Interventional |
Not Applicable |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of treatment-emergent adverse events (safety)
- Growth of new hair
- Change in hair thickness
|
8 |
All |
18 Years to 60 Years (Adult) |
NCT02626780 |
GIDAA-01 |
|
December 2015 |
February 2017 |
February 2017 |
December 10, 2015 |
May 1, 2017 |
|
- Maxwell Aesthetics
Nashville, Tennessee, United States - Renew Associates
San Antonio, Texas, United States
|
| 40 |
NCT02280603 |
Completed |
Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application |
|
- Drug: DA-4001C
- Drug: 5% minoxidil
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in target area hair count per cm2 at week 24, as assessed by phototrichogram
- Change from baseline in target area hair count per cm2 at week 16, as assessed by phototrichogram
- Improvement rate of target area hair count per cm2 at week 16 and week 24, as assessed by phototrichogram
- Improvement rate of target area mean hair diameter at week 16 and week 24, as assessed by phototrichogram
|
60 |
Male |
18 Years to 49 Years (Adult) |
NCT02280603 |
DA4001_AGAP_POC |
|
January 2014 |
December 2014 |
December 2014 |
October 31, 2014 |
June 24, 2015 |
|
- Catholic Medical Center
Seoul, Dongdaemun-gu, Korea, Republic of
|
| 41 |
NCT02150187 |
Completed |
Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss |
|
- Dietary Supplement: HCap Formula
- Dietary Supplement: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Changes in Terminal Hair Count at 26 Weeks Compared to Baseline
- Global Assessment of Improvement from Baseline to 26 and 52 weeks Assessed for Vertex and Frontal Views Separately
|
33 |
Male |
18 Years to 40 Years (Adult) |
NCT02150187 |
ProHair01 |
|
May 2014 |
February 2015 |
May 2015 |
May 29, 2014 |
July 18, 2017 |
|
- Dr David Friedman Laser & Skin Center
Jerusalem, Israel
|
| 42 |
NCT02393040 |
Unknown † |
Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia |
- Androgenetic Alopecia
- Alopecia
- Hair Loss
|
|
Interventional |
Not Applicable |
- Universitat Internacional de Catalunya
|
Other |
- Intervention Model: Single Group Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Determine the treatment efficacy by measuring hair regrowth score for each side of scalp.
- Determine the treatment efficacy by measuring hair density for each side of scalp
- Determine the treatment efficacy by measuring anagen/telogen ratio for each side of scalp
- Global photographs of three areas of the scalp (evaluation of hair growth will be assessed by comparison of standardized images)
|
50 |
All |
18 Years to 65 Years (Adult) |
NCT02393040 |
UICatalunya |
PRP |
January 2014 |
July 2015 |
November 2015 |
March 19, 2015 |
March 19, 2015 |
|
- Universitat Internacional Catalunya
Barcelona, Spain
|
| 43 |
NCT00396175 |
Completed |
Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) |
|
- Drug: MK0906, finasteride / Duration of Treatment : 48 Weeks
- Drug: Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
|
Interventional |
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Serum Prostatic Specific Antigen (PSA) after 48 weeks of treatment
- Reversibility of effects on Serum Prostatic Specific Antigen (PSA) after 24 weeks off drug
|
355 |
Male |
40 Years to 60 Years (Adult) |
NCT00396175 |
0906-111
2006_556 |
|
March 1998 |
January 2000 |
|
November 6, 2006 |
September 26, 2014 |
|
|
| 44 |
NCT00151515 |
Completed |
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss |
|
|
Interventional |
Phase 3 |
- Johnson & Johnson Consumer and Personal Products Worldwide
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean change in non-vellus hair count in the target region as determined by validated computer-assisted dot-mapping technique and subject ratings
- Visual assessment of local dermatitis
- Vital Signs
- (and 5 more...)
|
352 |
Male |
15 Years to 49 Years (Child, Adult) |
NCT00151515 |
A6221001 |
|
October 2003 |
July 2004 |
July 2004 |
September 9, 2005 |
September 30, 2016 |
|
- Pfizer Investigational Site
La Jolla, California, United States - Pfizer Investigational Site
San Francisco, California, United States - Pfizer Investigational Site
Vallejo, California, United States - (and 12 more...)
|
| 45 |
NCT03388840 |
Recruiting |
Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction |
|
- Biological: Adipose derived stem cells suspention
- Biological: Platelet rich plasma
- Other: normal saline
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- hair growth
- hair shaft diameter
|
45 |
Male |
18 Years to 60 Years (Adult) |
NCT03388840 |
ADSCPRPFUE |
|
January 15, 2018 |
January 2019 |
March 2019 |
January 3, 2018 |
February 14, 2018 |
|
- Assiut university hospitals
Assiut, Egypt
|
| 46 |
NCT03474718 |
Not yet recruiting
New |
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia |
|
- Biological: Platelet-rich Plasma Left Side
- Biological: Platelet-rich Plasma Right Side
|
Interventional |
Early Phase 1 |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Severity of Alopecia Tool (SALT) from baseline
- Change in Hair Count (number of hairs/0.65cm^2)
- Change in Hair Density (number of hairs/cm^2)
|
16 |
Female |
18 Years and older (Adult, Senior) |
NCT03474718 |
IRB00045844 |
|
May 2018 |
May 2020 |
May 2020 |
March 22, 2018 |
March 26, 2018 |
|
|
| 47 |
NCT02594046 |
Completed |
The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia |
|
- Other: stem cell component extract
|
Interventional |
Not Applicable |
- Pusan National University Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- change of total hair counts by phototrichogram
|
38 |
All |
19 Years to 59 Years (Adult) |
NCT02594046 |
L-2015-199-2 |
|
July 1, 2015 |
February 28, 2016 |
May 28, 2016 |
November 2, 2015 |
April 5, 2017 |
|
|
| 48 |
NCT01686295 |
Unknown † |
24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness |
|
- Device: iRestore Hair Rejuvenation System
- Device: sham device
|
Interventional |
Not Applicable |
- Freedom Laser Therapy, Inc.
- TKL Research, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Screening/Baseline Hair Growth at Week 12 and Week 24
- Visual Scalp Assessment
|
100 |
All |
25 Years to 60 Years (Adult) |
NCT01686295 |
CS940112 |
|
July 2012 |
April 2013 |
May 2013 |
September 18, 2012 |
September 18, 2012 |
|
- TKL Research Inc.
Paramus, New Jersey, United States
|
| 49 |
NCT02460497 |
Completed |
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia |
- Female Pattern Hair Loss, Androgenic Alopecia
|
- Drug: Treatment: Minoxidil 2% / Botanical Hair Solution for Women
|
Interventional |
Not Applicable |
- Galderma Laboratories, L.P.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator Global Photograph Rating
- Subject Rating
- Hair Wash/Shed Hair Count
- (and 2 more...)
|
61 |
Female |
18 Years to 60 Years (Adult) |
NCT02460497 |
GLI.04.SPR.US10330 |
|
May 2015 |
November 2015 |
November 2015 |
June 2, 2015 |
January 21, 2016 |
|
- Stephens & Associates
Richardson, Texas, United States
|
| 50 |
NCT02460289 |
Completed |
Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia |
- Male Pattern of Hair Loss, Androgenic Alopecia
|
- Drug: Treatment: Minoxidil 5% / Botanical Hair Solution for Men
|
Interventional |
Not Applicable |
- Galderma Laboratories, L.P.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Investigator Global Photograph Rating
- Subject Rating
- Hair Wash/Shed Hair Count
- Subject Satisfaction Questionnaire
|
63 |
Male |
18 Years to 60 Years (Adult) |
NCT02460289 |
GLI.04.SPR.US 10329 |
|
May 2015 |
November 2015 |
November 2015 |
June 2, 2015 |
January 21, 2016 |
|
- Stephens & Associates
Richardson, Texas, United States
|
Create an RSS feed from your search for:
Download the search results for: